We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Tag: Polypoidal Choroidal Vasculopathy
MedXY News
EnglishTag

Polypoidal Choroidal Vasculopathy

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersartificial intelligencetype 1 diabetesclinical trialsHypertensiononcologyCardiologyMortalitypublic healthcardiovascular diseasediabetesAlzheimer's diseaseepidemiologybreast cancer

Latest news

Tag

Evaluating Aflibercept With Reduced-Fluence Photodynamic Therapy in Polypoidal Choroidal Vasculopathy: Insights from Longitudinal OCT Angiography
newsafliberceptophthalmology

Evaluating Aflibercept With Reduced-Fluence Photodynamic Therapy in Polypoidal Choroidal Vasculopathy: Insights from Longitudinal OCT Angiography

By MedXY|Oct 9, 2026

This randomized trial compares aflibercept monotherapy versus combined with reduced-fluence photodynamic therapy for PCV, highlighting OCTA metrics that predict polypoidal lesion closure and treatment response over 52 weeks.

Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review
Clinical Updates
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Polypoidal Choroidal Vasculopathy
OCT Biomarkers

Outcomes of As-Needed Aflibercept Treatment After Complete Regression in Polypoidal Choroidal Vasculopathy: A Clinical Review

By MedXY|Sep 22, 2026

This review synthesizes evidence on PRN aflibercept treatment after complete polypoidal regression in PCV, highlighting recurrence rates, visual outcomes, and potential OCT biomarkers guiding individualized management.

Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD
newschoroidal thicknessneovascular AMD

Predictors of 1-Year Visual Outcome in Central-Involving Submacular Hemorrhage Secondary to Neovascular AMD

By MedXY|May 27, 2026

This study found that younger age, better baseline vision, smaller hemorrhage size, and thicker subfoveal choroid predicted better 1-year visual outcomes after fovea-involving submacular hemorrhage from nAMD or PCV.

High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy
newsPolypoidal Choroidal Vasculopathyretinal diseases

High-Dose Aflibercept 8 mg Demonstrates Sustained Visual Gains and Durability in Polypoidal Choroidal Vasculopathy

By MedXY|Dec 24, 2025

This post hoc analysis of the PULSAR trial reveals that aflibercept 8 mg provides noninferior visual outcomes and comparable anatomic regression to standard 2 mg dosing in PCV patients, while allowing for significantly extended treatment in

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Cardiology
Precision Medicine for Long QT Syndrome Type 2: Lumacaftor Corrects Trafficking Defects and Shortens QT Interval
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models